Symbiotec Pharmalab’s initial public offering (IPO) is set to list on the Indian stock market tomorrow, September 1. The IPO was oversubscribed 73.63 times by non-institutional investors, signaling strong demand. The grey market premium (GMP) currently stands at +203, suggesting the shares may list above the IPO price of ₹988, according to livemint.com.
The IPO subscription process saw significant interest from retail investors, with the non-institutional investor category driving the oversubscription. The GMP, which reflects the premium investors are willing to pay over the IPO price in unofficial markets, indicates positive sentiment ahead of the listing. Market participants have been closely watching the GMP as a barometer of listing day performance, as reported by livemint.com.
The strong oversubscription and high GMP underscore robust investor appetite for Symbiotec Pharmalab’s shares, positioning it among the notable IPOs in the Indian pharmaceutical sector this year. The company’s pricing at ₹988 per share and the subsequent premium in the grey market align with trends seen in other well-received pharma IPOs, which have attracted substantial retail participation and delivered listing gains.
Symbiotec Pharmalab’s shares will debut on the stock exchange on September 1, with the GMP of +203 indicating a potential listing price around ₹1,191 per share. Investors and market watchers will observe the listing closely to gauge the stock’s initial market performance.